Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma

JAMA Dermatology

Volumn 152, Issue 4, 2016, Pages 452-456

  Ally, Mina S ^a   Ransohoff, Katherine ^a,b   Sarin, Kavita ^a   Atwood, Scott X ^b   Rezaee, Melika ^a   Bailey Healy, Irene ^a   Kim, Jynho ^b   Beachy, Philip A ^b   Chang, Anne Lynn S ^a   Oro, Anthony ^a,b   Tang, Jean Y ^a   Colevas, A Dimitrios ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CARBOPLATIN; CREATININE; GLI FAMILY ZINC FINGER 1; ITRACONAZOLE; LEQ 506; MESSENGER RNA; NITROGEN; PACLITAXEL; PATIDEGIB; PROTEIN INHIBITOR; SMOOTHENED PROTEIN INHIBITOR; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TALADEGIB; UNCLASSIFIED DRUG; UREA; VISMODEGIB; ZINC FINGER PROTEIN; ANTINEOPLASTIC AGENT; GLI1 PROTEIN, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GLI1;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAPHY; FOLLOW UP; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; GLI1 GENE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; INFECTION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; REFRACTORY METASTATIC BASAL CELL CARCINOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UREA NITROGEN BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; CARCINOMA, BASAL CELL; DRUG RESISTANCE; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CARCINOMA, BASAL CELL; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HEDGEHOG PROTEINS; HUMANS; ITRACONAZOLE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OXIDES; RNA, MESSENGER; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; ZINC FINGER PROTEIN GLI1;

EID: 84963775861     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.5473     Document Type: Article

References (19)

1. Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol. 2013;149(5):615-616.
2. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-2179.
3. National Comprehensive Cancer Network. Basal cell skin cancer. 2015; https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn .org/professionals/physician-gls/pdf/nmsc.pdf. Accessed June 14, 2015.
4. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180-2188.
5. Atwood SX, Sarin KY, Whitson RJ, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015; 27(3):342-353.
6. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388-399.
7. Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745-751.
8. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA. Arsenic antagonizes the hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Natl Acad Sci U S A. 2010;107(30):13432-13437.
9. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23-34.
10. clinicaltrials.gov. Arsenic Trioxide in Treating PatientsWith Basal Cell Carcinoma. NCT01791894. https://clinicaltrials.gov/ct2/show/NCT01791894 ?term=NCT01791894&rank=1. Accessed September 5, 2014.
11. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group.AmJ Clin Oncol. 1982;5(6):649-655.
13. Kindler HL, Aklilu M, Nattam S, Vokes EE. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol. 2008;31(6):553-556.
14. Gomez-Ospina N, Chang AL, Qu K, Oro AE. Translocation affecting sonic hedgehog genes in basal-cell carcinoma. N Engl J Med. 2012;366(23): 2233-2234.
15. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011;71(15): 5057-5061.
16. Wang XD, Inzunza H, Chang H, et al. Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors. PLoS One. 2013;8(1):e54415.
17. George B, Mathews V, Poonkuzhali B, Shaji RV, Srivastava A, Chandy M. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience. Leukemia. 2004;18(10):1587-1590.
18. Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013;31(33):4215-4221.
19. Chang AS. Open-label pilot study of LDE225 in advanced basal cell carcinoma patients who have been treated previously with a non-LDE225 Smoothened inhibitor. J Invest Dermatol. 2014;134 (suppl 1):S101.